Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.

NCT00465491 is registered in ClinicalTrials.gov with Poniard Pharmaceuticals as lead sponsor.

NCT NCT00465491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00465491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy.
Lead sponsor
Poniard Pharmaceuticals
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2007
Completion date
Not reported
Enrollment
399 (estimated)
Sites
143

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer